Impact of Integrase Sequences from HIV-1 Subtypes A6/A1 on the <i>In Vitro</i> Potency of Cabotegravir or Rilpivirine
Jerry L. Jeffrey, Marty St. Clair, Ping Wang, Chunfu Wang, Zhufang Li, Jagadish Beloor, Christine Talarico, Robert Fridell, Mark Krystal, C. Thomas White, Sandy Griffith, Ronald D’Amico, Kimberly Smith, Veerle Van Eygen, Johan Vingerhoets, Kati Vandermeulen, William Spreen, Jan van Lunzen
Abstract
The FLAIR study demonstrated noninferiority of monthly long-acting cabotegravir + rilpivirine versus daily oral dolutegravir/abacavir/lamivudine for maintaining virologic suppression. Three participants who received long-acting therapy had confirmed virologic failure (CVF) at Week 48, and all had HIV-1 that was originally classified as subtype A1 and contained the baseline integrase polymorphism L74I; updated classification algorithms reclassified all 3 as HIV-1 subtype A6.